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susceptibility testingMethods: From September 2009 to October 2012, four postpartum women developed C-section
wound infections caused by M. massiliense. Speciation of the four isolates was identified using
of hsp65, rpoB, and secA1 partial gene sequencing and the Basic Local Alignment Search Tool.
The erm(41) and rrl genes were detected for the possibility of inducible macrolide resistance.
Pulsed-field gel electrophoresis was used as a tool of molecular epidemiology. All patients un-
derwent intensive intravenous and oral antimycobacterial regimens. Of these patients, three
underwent debridement at least once.
Results: All four isolates were identified as M. abscessus subsp. massiliense. All of the isolates
harbored a truncated erm(41) gene without rrl gene mutations, which explains the susceptibil-
ity to clarithromycin and azithromycin. Three isolates were indistinguishable by DNA strain
typing, and the fourth strain was clonal with the other three strains. Their infections were
not improved in spite of teicoplanin treatment initially. These patients underwent antimyco-
bacterial regimens with/without surgery and were all cured.
Discussion: Teicoplanin treatment failure, painful cutaneous nodules, and persistent wound
drainage alerted us to the possibility of nontuberculous mycobacterial skin and soft tissue
infection. Accurate identification of subspecies, detection of drug resistance genes, suscepti-
bility testing, and optimal antimycobacterial agents with/without surgical debridement are
warranted for successful treatment.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The Mycobacterium abscessus complex is ubiquitous in the
environment, including in soil and water, and has often
been incriminated in cases of wound and soft tissue infec-
tion.1 Although the M. abscessus complex has frequently
been described in cases of wound infection following
cosmetic surgery, we only found one published case of
postsurgical wound infection following cesarean section (C
section) involving the M. abscessus complex.2
The current taxonomy of the M. abscessus complex is
controversial. The complex is now thought to consist of three
subspecies: M. abscessus subsp. abscessus, M. abscessus
subsp. massiliense, and M. abscessus subsp. bolletii.3,4 In
2011, Leao et al5 proposed the reclassification of subspecies
massiliense and subspecies bolletii into one subspecies to be
designated M. bolletii, following taxonomic rules of prece-
dence. However, recent whole genomic studies have sub-
stantiated the presence of three separate subspecies,
designated as M. abscessus subsp. abscessus, M. abscessus
subsp. bolletii, and M. abscessus subsp. massiliense.3,4
Hereafter, for brevity, these subspecies will be referred to
in this paper as M. abscessus, M. bolletii, and M. massi-
liense.5,6 The importance of differentiating theM. abscessus
complex into three subspecies has beenemphasized recently
especially with consideration of treatment regimens.7
Following investigation of a rare wound infection case
caused byM. abscessus in our hospital in September 2009, we
focused on the causal relationship between M. abscessus
complex and post C-section wound infections and identified
four patients with cultures that tested positive for rapidly
growing mycobacteria (RGM). Four clinical isolates were
subsequently identified as M. abscessus subsp. massiliense
using the partial hsp65, rpoB, and secA1 genes sequencing,
which were analyzed with Basic Local Alignment Search Tool
(BLAST) in theNational Center for Biotechnology Information
(NCBI) website.Prior to the discovery of the erm gene, which is known to
induce macrolide resistance in many species of rapidly
growing mycobacteria including M. abscessus, clari-
thromycin was included in most treatment regimens for M.
abscessus.8,9 The presence of the erm(41) gene has been
responsible for the induction of clarithromycin resistance in
the majority of the isolates of M. abscessus subsp. absces-
sus. However, erm(41) is nonfunctional in isolates of M.
massiliense rendering them macrolide susceptible, even
after extended incubation.10 In order to determine the
optimal antimycobacterial regimens for M. abscessus subsp.
massiliense soft tissue infection, we performed in vitro
susceptibility testing on the four strains.
Recent advances in clinical mycobacteriology have
focused on the molecular epidemiology, subspecies identi-
fication, the relationship between erm(41) gene and
inducible macrolide resistance, and the selection of anti-
mycobacterial agents in relation to clinical outcomes.Methods
Patients/clinical data
Wound or tissue cultures collected at Chang Gung Memorial
HospitaleLinkou Medical Center, Kwei-Shan, Taoyuan,
Taiwan from September 1, 2009 to October 31, 2012 from
four postpartum patients were positive for M. massiliense.
The first isolate was collected in 2009, and the other three
were collected in 2012. Demographic data including age,
comorbidities, symptoms and signs, the incubation period
(from the date of operation to the date of onset of symp-
toms), human immunodeficiency virus antigen and antibody
(HIV Ag/Ab) tests data, and treatment modalities were
abstracted from the medical records. The anti-
mycobacterial agents included the following: oral azi-
thromycin (250 mg) two tablets once daily, or oral
M. massiliense C-section wound infection 957clarithromycin (500 mg) one tablet twice daily, oral moxi-
floxacin (400 mg) one tablet once daily, imipenem/cil-
astatin (500 mg/500 mg) intravenous infusion one vial every
6 hours, tigecycline (50 mg) intravenous infusion two vials
for loading, then one vial every 12 hours, and amikacin
(500 mg) intravenous infusion one vial for loading, and
7.5 mg/kg every 12 hours. Surgical therapy, including fas-
ciotomy for deep-seated surgical site infection, and incision
and drainage for superficial surgical site infection was
performed. The classification of surgical site infection is
according to the definition proposed by the Centers for
Disease Control and Prevention.11 Outcomes were classified
as follows: (1) successfuldcomplete remission of tissue
erythema, tenderness, swelling without residual pus
discharge, and good healing of C-section wound; (2) fail-
eddincomplete remission of tissue erythema, tenderness,
swelling, or persistent residual pus discharge, and poor
healing of C-section wound.
Microbiological identification by hsp65, rpoB, and
secA1 partial gene sequencing
The forward and reverse primers for hsp65 were Tb11 (50-
ACCAACGATGGTGTGTCCAT-30) and Tb12 (50-CTTGTCGA
ACCGCATACCCT-30) amplified a 439-bp fragment; for rpoB,
the primers were Myco-F (50-GGCAAGGTCACCCCGAAGGG-
30) and Myco-R (50-AGCGGCTGCTGGGTGA-TCATC-30); for
secA1, the primers were Mtu.For1 (50-GA-CAGY-
GAGTGGATGGGYCGSGTGCACCG-30) and Mtu.Rev490 (50-
GCGGACGATGTARTCCTTGTCSCG-30). The polymerase chain
reaction conditions were the same as those in the methods
described by Zelazny et al.12 The amplicons were sent to
Tri-I Biotech, Inc. (New Taipei, Taiwan) for sequencing. The
isolates were sequenced using an ABI 3730 genetic analyzer
(Applied Biosystem, Carlsbad, CA, USA). Genetic sequences
were analyzed (http://blast.ncbi.nlm.nih.gov) and
compared to the NCBI database using BLAST.
Partial erm(41) and rrl genes sequencing
Partial erm(41) sequencing followed the method described
by Maurer et al.13 with the forward primer (50-
GGCCTTCTTCGTGATCTATCG-30) and reverse primer (50-
CACCGATTCCACCGGTTAG-30). The rrl gene was amplified
using primers SP1 (50-CCTGCACGAATGGCGTAACG-30) and
SP2mod (50-CACCAGAGGTTCGTCCGTC-30). The amplified
fragments were purified using the EasyPure PCR/Gel
Extraction Kit (Bioman Corp., New Taipei, Taiwan). The
purified fragments were sequenced in the Applied Bio-
systems 3730 genetic analyzer (Applied Biosystems, Carls-
bad, CA, USA). Genetic sequences were analyzed using
nucleotide BLAST offered by the NCBI.
In vitro susceptibility testing
Using broth microdilution, we determined the minimum
inhibitory concentrations (MICs) according to the guidelines
proposed by the Clinical and Laboratory Standards Institute
(CLSI).14 Isolates were subcultured on Middlebrook 7H11agar plates and incubated at 30C for 3 days. The inoculum
was prepared in cation-adjusted MuellereHinton broth to
match the density of a 0.5 McFarland standard. Following
dilution to a 1e5  106 per mL suspension, 10 mL was
dispensed into 100 mL of cation-adjusted MuellereHinton
broth and subsequently inoculated into 96-well plates to
yield a final density of 1e5  104 in each well.
The antimicrobial test agents included amikacin (AMK),
isepamicin (ISP), azithromycin (AZI), clarithromycin (CLR),
doxycycline (DOX), minocycline (MIN), tigecycline (TGC),
cefoxitin (FOX), ciprofloxacin (CIP), levofloxacin (LVX),
moxifloxacin (MXF), imipenem (IPM), meropenem (MPM),
trimethoprim/sulfamethoxazole (SXT), and linezolid (LZD).
Panels were incubated for 3 days at 30C in roomair. Using
a mirrored light box, the MIC was read as the first well in
which therewas no growth, except for SXT, for which theMIC
was 80% inhibitionof growth compared to the control growth.
The intermediate breakpoints (in mg/mL) of these antibiotics
(except AZI, ISP, LVX, and TGC, which do not have CLSI
breakpoints), were those proposed by the CLSI, with
AMK Z 32, FOX Z 32e64, CIP Z 2, CLR Z 4, DOX Z 2e4,
IPMZ 8e16, LZDZ 16, MPMZ 8e16, and MXFZ 2.
Mycobacterium peregrinum ATCC 700686 was used for
quality control of the panels with acceptable MIC ranges
recorded in mg/mL as follows: AMK  1e4, FOXZ 4e32, CIP
0.12e0.5, CLR 0.06e0.5, DOXZ 0.12e0.5, IPMZ 2e16,
LZD Z 1e8, MPM Z 2e16, MIN Z 0.12e0.5, MXF
0.06e0.25, and SXT 0.25/4.8e2/38 following CLSI
recommendations.14Pulsed-field gel electrophoresis
The protocols proposed by Zhang et al.15 were followed
with minor modifications. Briefly, M. massiliense isolates
cast into low-melting-point agarose plugs were lysed with
lysozyme, sodium dodecyl sulfate, and proteinase K. The
genomic DNA contained in the plugs was digested with re-
striction endonucleases AseI (New England BioLabs, Ips-
wich, MA, USA) and separated by pulsed-field gel
electrophoresis (PFGE) with a CHEF Mapper system (Bio-
Rad Laboratories, Richmond, CA, USA). PFGE gels were run
in regular 0.5 TriseborateeEDTA buffer (50mM Tris, 45mM
boric acid, and 0.5mM EDTA) plus 200mM thiourea. An
autoalgorithm mode was chosen with the running molecu-
lar weights ranging from 20 kb to 380 kb. The gel was
stained with ethidium bromide and photographed under UV
illumination for analysis. The band sizes, in kilobase (kb)
pairs, were estimated using Phoretix 1D Pro software
(TotalLab Ltd., Newcastle upon Tyne, NE, UK) with a
lambda ladder and a 48.5-kb ladder as the molecular size
standards.
Differences between PFGE profiles were determined,
and strain relatedness was determined by use of a modifi-
cation of the definitions recommended by Tenover et al.16
Isolates were considered indistinguishable, closely
related, or possibly related if they exhibited zero, two to
three, or four to six band differences, respectively. In all
these circumstances, the isolates were considered clonal.
Isolates were considered not related if they exhibited seven
or more band differences.
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958 T.-S. Wu et al.Ethics statement
The study was approved by the Institutional Review Board
of the Chang Gung Memorial HospitaleLinkou Medical
Center in September 2012. Patients were requested to give
written informed consent for the storage and use of their
data. No linkage of these data with other sources was done.
No patient identifiers were included in the dataset used for
this analysis. All bacterial strains were obtained from the
Bacteria Bank, Department of Laboratory Medicine, Chang
Gung Memorial Hospital.
Results
Patients/clinical data
Four patients’ demographic data, HIV Ag/Ab status,
treatment, and outcomes were collected. The patients’
ages ranged from 30 years to 34 years. The indications of
C-section were two breech presentations, one cepha-
lopelvic disproportion, and one chorioamnionitis. Two of
them had thalassemia, one of whom was also a hepatitis B
carrier. The presentations of these patients’ surgical site
infections were four painful subcutaneous nodules, two
wounds with marked erythema, and one surgical wound
dehiscence (Figure 1). The incubation period (from the
date of the operation to the date of onset of symptoms) of
four patients was from 53 days to 97 days. Three patients
had superficial surgical site infections. One patient
developed a deep surgical site infection. Three of the
patients underwent surgical debridement one to three
times in addition to antimycobacterial therapy. The fourth
patient received only antimycobacterial therapy without
surgical debridement. Two of the patients had coagulase
negative Staphylococcus coinfection; one patient had
methicillin-resistant Staphylococcus aureus coinfection.
These three patients underwent teicoplanin treatment for
2 weeks (data not shown in Table 1) but continued with
persistent wound drainage. All four patients receivedFigure 1. The cesarean section wound infected with Myco-
bacterium massiliense. Arrow Z wound erythema;
arrowhead Z wound dehiscence and drainage site; star Z
painful cutaneous nodule.
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M. massiliense C-section wound infection 959antimycobacterial therapy for w6 months. The regimens
included oral macrolides (azithromycin or clarithromycin),
oral moxifloxacin or intravenous moxifloxacin, intravenous
amikacin, intravenous imipenem/cilastatin, and intrave-
nous tigecycline. Fortunately, all of the patients were
cured with antimycobacterial therapy with/without sur-
gical debridement.
Microbiological identification
The four isolates were identified as M. massiliense using the
partial hsp65, the rpoB, and secA1 genes sequencing. The
data were analyzed using BLAST on the NCBI website.
Partial erm(41) and rrl genes sequencing
The erm(41) gene sequences of all four isolates were of the
same length (249 bp), which is shorter than that of M.
abscessus ATCC 19977T. Compared with the sequence of M.
abscessus ATCC 19977T, the erm(41) sequence of M. mas-
siliense lacked 273 bp length because of two characteristic
deletions (bases 61e62 and 159e429). The rrl gene
sequencing revealed the same wild type as that of M.
abscessus ATCC 19977T.
Antimicrobial susceptibility testing
All four isolates of M. massiliense were resistant to DOX,
MIN, CIP, MXF, MPM, SXT, and LZD, and susceptible to AMK
and CLR. We regarded all four isolates as susceptible to
AZI as CLR is the class drug for the new macrolides
including AZI.14 CIP is the class drug for CIP and LVX; thus,
the CIP MIC predicts LVX MICs but not MXF. Isolates 1, 2,
and 3 were susceptible to FOX and IPM. Isolate 4 was in-
termediate susceptible to FOX and IPM. There is no
breakpoint of TGC for RGM; however, all isolates had TGC
MICs (1 mg/mL).Figure 2. Pulsed-field gel electrophoresis of four presenting
Mycobacterium massiliense isolates from patients with post-
partum cesarean section wound infections.Genotyping
The PFGE patterns of the three isolates of M. massiliense
were indistinguishable, and the fourth was clonal with the
other three isolates (Figure 2). Lane 1 of Figure 2 repre-
sents the genotype of an isolate from a case outside the
time of the other three cases.Discussion
M. massiliense skin and soft tissue infection is also difficult
to differentiate from other nontuberculous mycobacterial
cutaneous infection or nocardia soft tissue infection,17,18 as
the clinical presentations, such as persistent subcutaneous
tender nodule, skin erythema, and unhealing wound, are
similar. All four isolates were identified as M. massiliense
and possessed a truncated erm(41) gene without rrl gene
mutations, rendering the gene nonfunctional and incapable
of inducing resistance to clarithromycin and azithromycin
in contrast to M. abscessus, for which the majority of iso-
lates harbor an inducible erm(41) gene, and M. bolletii,
which is intrinsically resistant to macrolides. This finding is
the same as that reported by Kim et al.19 and Maurer
et al.20
By PFGE, three of the four isolates of M. massiliense
were indistinguishable and the first was clonal with the
other three isolates. The latter three isolates presented
one cluster, which reminded us of the importance of
seeking for the common source of infection. With the help
of Infection Control Practitioners, environmental speci-
mens such as tap water, swabs of inner wall of washbasins,
gel for fetal heart beats sonogram, cleaning liquid soap for
abdomen, providoneeiodine solution, and sterilized saline
solution for irrigation for peritoneal cavity were all
collected for bacterial and mycobacterial cultures. Bacte-
rial cultures of gel for fetal heartbeat sonogram yielded
Escherichia coli and glucose-nonfermenting gram-negative
bacilli. M. massiliense was not detected in any of the
environmental cultures. As the identification of a single
common infection focus is difficult, strict compliance with
infection control measures is of paramount importance to
prevent surgical site infection.
The most common causative microbes for C-section
wound infection were Streptococci, followed by E. coli and
Bacteroides species.21 Although publications regarding
plastic surgery or cosmetic surgery related to M. abscessus
surgical site infections are plentiful,22e24 we found only one
previous publication related to M. abscessus in a C section-
related surgical site infection.2 In the article, 13
laboratory-confirmed M. abscessus infected post C-section
patients were treated by oral clarithromycin, intravenous
imipenem/cilastatin, and intravenous amikacin. Among
these 13 patients, 10 had satisfactory outcomes, but three
had unknown posttreatment outcomes. Antimicrobial sus-
ceptibility patterns and erm(41) gene polymorphisms were
not known in this study. The longest treatment course used
in this study was 24 months. The American Thoracic Soci-
ety/Infectious Disease Society of America recommends
combination therapy for the treatment of most postsurgical
infections involving the M. abscessus complex.8 In most
prior cases of published M. massiliense infections,
960 T.-S. Wu et al.combination therapy was used. In other studies, the au-
thors reported successful experiences in treatment of M.
abscessus complex infections with the concomitant use of
macrolides with amikacin, fluoroquinolones, imipenem/
cilastatin, or cefoxitin.25e28 A few cases were successfully
treated with only oral clarithromycin.29,30 Most published
regimens included clarithromycin alone or in combination
therapy.
In our study, we implemented a strategy including oral
clarithromycin, intravenous tigecycline (or imipenem/cil-
astatin, or moxifloxacin), and intravenous amikacin for the
treatment of patients with post C-section infections. The
patients were subsequently maintained with oral clari-
thromycin, and moxifloxacin with/without daily intramus-
cular injection of amikacin. All four patients underwent
antimycobacterial therapy as long as 6 months, and three
of them underwent surgical debridement. One patient only
received antimycobacterial agents without surgical
debridement. All patients had satisfactory outcomes
without any sequelae. We chose tigecycline as one member
of our combination regimens, because it is not only effec-
tive against RGM but is also effective for complicated skin
and soft tissue infections.31 In a clinical trial initiated by
Wallace et al.,32 tigecycline-containing regimens were
successfully prescribed to treat six of eight (75%) cases of
complicated M. abscess complex or Mycobacterium chelo-
nae skin and soft tissue infections. It is noteworthy that a
high percentage of adverse reactions such as nausea and/or
vomiting is present in tigecycline-containing regimens. In
certain situations, once daily dose or prolonged infusion
perhaps can decrease the adverse reactions, but it was not
proven clinically effective against M. massiliense skin and
soft tissue infections. Sequential oral macrolide and moxi-
floxacin therapy is reasonable because treatment with
clarithromycin and fluoroquinolone produced satisfactory
outcomes in M. massiliense pulmonary infection as re-
ported by Koh et al.7,26
In conclusion, subspecies identification, drug-resistant
gene detection, susceptibility testing, and selection of
optimal antimycobacterial agents are warranted for the
successful treatment of M. massiliense skin and soft tissue
infections.Conflicts of interests
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